Dermatologic Manifestations Induced By Immune Responses After Covid-19 Vaccination
DOI:
https://doi.org/10.56294/saludcyt20251628Keywords:
Immunologic reactions, COVID-19, CoronaVac, dermatologic diseasesAbstract
Immunologic reactions induced by COVID-19 vaccines can manifest in the skin, triggering adverse effects of varying intensity. Although most of these reactions are self-limited and not significant, their identification is complex due to the variability of stimuli affecting the skin. In many cases, these manifestations appear after the second or third dose and tend to resolve without intervention. Patients with a history of allergy are more prone to adverse reactions with the BNT162b2 vaccine, although they can be vaccinated under medical supervision. A total of 133 skin reactions were reported following administration of CoronaVac, including urticaria, angioedema, pityriasis rosea, herpes zoster and maculopapular rashes, while BioNTech has been associated with cases of anaphylaxis and activation of autoimmune diseases. This observational, descriptive and retrospective study is based on a systematic review and meta-analysis of reliable scientific sources, with the purpose of examining the relationship between immune responses and dermatological diseases following vaccination against SARS-CoV-2.
References
1. Burlando M, Herzum A, Micalizzi C, Cozzani E, Parodi A. Cutaneous reactions to COVID‐19 vaccine at the dermatology primary care. Immun Inflamm Dis [Internet]. 2022;10(2):265–71. Available from: http://dx.doi.org/10.1002/iid3.568
2. Seirafianpour F, Pourriyahi H, Gholizadeh Mesgarha M, Pour Mohammad A, Shaka Z, Goodarzi A. A systematic review on mucocutaneous presentations after COVID‐19 vaccination and expert recommendations about vaccination of important immune‐mediated dermatologic disorders. Dermatol Ther [Internet]. 2022;35(6). Available from: http://dx.doi.org/10.1111/dth.15461
3. Cantisani C, Chello C, Grieco T, Ambrosio L, Kiss N, Tammaro A, et al. Cutaneous reactions to COVID-19 vaccines in a monocentric study: A case series. J Clin Med [Internet]. 2022;11(13):3811. Available from: http://dx.doi.org/10.3390/jcm11133811
4. Shavit R, Maoz-Segal R, Iancovici-Kidon M, Offengenden I, Haj Yahia S, Machnes Maayan D, et al. Prevalence of allergic reactions after Pfizer-BioNTech COVID-19 vaccination among adults with high allergy risk. JAMA Netw Open [Internet]. 2021;4(8):e2122255. Available from: http://dx.doi.org/10.1001/jamanetworkopen.2021.22255
5. Cebeci Kahraman F, Savaş Erdoğan S, Aktaş ND, Albayrak H, Türkmen D, Borlu M, et al. Cutaneous reactions after COVID‐19 vaccination in Turkey: A multicenter study. J Cosmet Dermatol [Internet]. 2022;21(9):3692–703. Available from: http://dx.doi.org/10.1111/jocd.15209
6. Tavakoli N, Nafissi N, Shokri S, Fallahpour M, Soleimani S, Riahi T, Kalantari S, Goodarzi A, Valizadeh R. Comparison of the onset and end of specific and major side effects in Iranian teenage participants vaccinated with COVID-19 vaccine: Sinopharm and soberana. Med J Islam Repub Iran [Internet]. 2023; Available from: http://dx.doi.org/10.47176/mjiri.37.15
7. Chérrez-Ojeda I, Robles-Velasco K, Osorio MF, Mejía-Leiva D, Chérrez A, Chérrez S, et al. Reacciones cutáneas a la vacuna Pfizer-BioNTech contra COVID-19. Una experiencia ecuatoriana. Revista Alergia México [Internet]. 2023;69(1):61–4. Available from: http://dx.doi.org/10.29262/ram.v69i1.973
8. Pan Y, Liu L, Tian T, Zhao J, Park CO, Lofftus SY, et al. Epicutaneous immunization with modified vaccinia Ankara viral vectors generates superior T cell immunity against a respiratory viral challenge. NPJ Vaccines [Internet]. 2021;6(1). Available from: http://dx.doi.org/10.1038/s41541-020-00265-5
9. Seree-aphinan C, Rattanakaemakorn P, Suchonwanit P, Thadanipon K, Ratanapokasatit Y, Yongpisarn T, et al. Immunogenicity of intradermal versus intramuscular BNT162b2 COVID-19 booster vaccine in patients with immune-mediated dermatologic diseases: A non-inferiority randomized controlled trial. Vaccines (Basel) [Internet]. 2024;12(1):73. Available from: http://dx.doi.org/10.3390/vaccines12010073
10. An Z, Figueroa-Parra G, Zhou X, Li Y, Jaquith J, McCarthy-Fruin K, et al. Immune responses and disease biomarker long-term changes following COVID-19 mRNA vaccination in a cohort of rheumatic disease patients. Front Immunol [Internet]. 2023;14. Available from: http://dx.doi.org/10.3389/fimmu.2023.1224702
11. Cheng A, Hsieh M-J, Chang S-Y, Ieong S-M, Cheng C-Y, Sheng W-H, et al. Correlation of adverse effects and antibody responses following homologous and heterologous COVID19 prime-boost vaccinations. J Formos Med Assoc [Internet]. 2023;122(5):384–92. Available from: http://dx.doi.org/10.1016/j.jfma.2022.12.002
12. Fendler A, Shepherd STC, Au L, Wilkinson KA, Wu M, Byrne F, et al. Adaptive immunity and neutralizing antibodies against SARS-CoV-2 variants of concern following vaccination in patients with cancer: the CAPTURE study. Nat Cancer [Internet]. 2021;2(12):1305–20. Available from: http://dx.doi.org/10.1038/s43018-021-00274-w
13. Picone V, Napolitano M, Martora F, Guerriero L, Fabbrocini G, Patruno C. Urticaria relapse after mRNA COVID ‐19 vaccines in patients affected by chronic spontaneous urticaria and treated with antihistamines plus omalizumab: A single‐center experience. Dermatol Ther [Internet]. 2022;35(11). Available from: http://dx.doi.org/10.1111/dth.15838
14. Gisondi P, Geat D, Bellinato F, Girolomoni G. Use of biologics during the COVID-19 pandemic: lessons learned from psoriasis. Expert Opin Biol Ther [Internet]. 2022;22(12):1521–9. Available from: http://dx.doi.org/10.1080/14712598.2022.2110467
15. Syrmou V, Liaskos C, Ntavari N, Mitsimponas K, Simopoulou T, Alexiou I, et al. COVID-19 vaccine-associated myositis: a comprehensive review of the literature driven by a case report. Immunol Res [Internet]. 2023;71(4):537–46. Available from: http://dx.doi.org/10.1007/s12026-023-09368-2
16. Kim BC, Kim HS, Han KH, Han SY, Jo HA. A case report of MPO-ANCA-associated vasculitis following heterologous mRNA1273 COVID-19 booster vaccination. J Korean Med Sci [Internet]. 2022;37(26). Available from: http://dx.doi.org/10.3346/jkms.2022.37.e204
17. McClatchy J, Yap T, Nirenberg A, Scardamaglia L. Fixed drug eruptions – the common and novel culprits since 2000. J Dtsch Dermatol Ges [Internet]. 2022;20(10):1289–302. Available from: http://dx.doi.org/10.1111/ddg.14870
18. Yatim N, Boussier J, Tetu P, Smith N, Bruel T, Charbit B, et al. Immune checkpoint inhibitors increase T cell immunity during SARS-CoV-2 infection. Sci Adv [Internet]. 2021;7(34). Available from: http://dx.doi.org/10.1126/sciadv.abg4081
19. Orun A, Kurugollu F. Progressive observation of covid-19 vaccination effects on skin-cellular structures by use of intelligent laser speckle classification (ILSC) technique. J Digit Imaging [Internet]. 2023;36(4):1701–11. Available from: http://dx.doi.org/10.1007/s10278-023-00795-z
20. Prins MLM, Prins C, de Vries JJC, Visser LG, Roukens AHE. Establishing immunogenicity and safety of needle-free intradermal delivery by nanoporous ceramic skin patch of mRNA SARS-CoV-2 vaccine as a revaccination strategy in healthy volunteers. Virus Res [Internet]. 2023;334(199175):199175. Available from: http://dx.doi.org/10.1016/j.virusres.2023.199175
21. Wang Z, Xiao Y, Wang M, Chen Q, Lin Y, Fang X, et al. Acupuncture as a therapeutic intervention for post-COVID-19 vaccination urticaria: a systematic review and meta-analysis protocol. BMJ Open [Internet]. 2023;13(10):e073914. Available from: http://dx.doi.org/10.1136/bmjopen-2023-073914
22. Eyer-Silva W de A, Leme LS de CP. Facial Angioedema after the first dose of Covishield (adenovirus-vectored severe acute respiratory syndrome coronavirus 2 vaccine): follow-up after the second and third booster doses. Rev Soc Bras Med Trop [Internet]. 2022;55. Available from: http://dx.doi.org/10.1590/0037-8682-0063-2022
23. Marty PK, Van Keulen VP, Erskine CL, Shah M, Hummel A, Stachowitz M, et al. Antigen specific humoral and cellular immunity following SARS-CoV-2 vaccination in ANCA-associated vasculitis patients receiving B-cell depleting therapy. Front Immunol [Internet]. 2022;13. Available from: http://dx.doi.org/10.3389/fimmu.2022.834981
24. Monteiro A, Chang AJ, Welliver RR, Baron S, Hicar MD. Humoral cross-coronavirus responses against the S2 region in children with Kawasaki disease. Virology [Internet]. 2022;575:83–90. Available from: http://dx.doi.org/10.1016/j.virol.2022.08.010
25. Genco L, Cantelli M, Noto M, Battista T, Patrì A, Fabbrocini G, et al. Alopecia areata after COVID-19 vaccines. Skin Appendage Disord [Internet]. 2023;9(2):141–3. Available from: http://dx.doi.org/10.1159/000528719
26. Apostolidis SA, Kakara M, Painter MM, Goel RR, Mathew D, Lenzi K, et al. Cellular and humoral immune responses following SARS-CoV-2 mRNA vaccination in patients with multiple sclerosis on anti-CD20 therapy. Nat Med [Internet]. 2021;27(11):1990–2001. Available from: http://dx.doi.org/10.1038/s41591-021-01507-2
27. Gil-Vila A, Ravichandran N, Selva-O’Callaghan A, Sen P, Nune A, Gaur PS, et al. COVID‐19 Vaccination in Autoimmune Diseases (COVAD) study: Vaccine safety in idiopathic inflammatory myopathies. Muscle Nerve [Internet]. 2022;66(4):426–37. Available from: http://dx.doi.org/10.1002/mus.27681
28. Ding Y, Ge Y. Inflammatory myopathy following coronavirus disease 2019 vaccination: A systematic review. Front Public Health [Internet]. 2022;10. Available from: http://dx.doi.org/10.3389/fpubh.2022.1007637
Downloads
Published
Issue
Section
License
Copyright (c) 2025 León Pallasco Dayana Aracely , Palma Coque Elio Joel , Paredes Tobar Sebastián Oswaldo , Miranda Solis Edwin Marcelo (Author)
This work is licensed under a Creative Commons Attribution 4.0 International License.
The article is distributed under the Creative Commons Attribution 4.0 License. Unless otherwise stated, associated published material is distributed under the same licence.
